Clinical trialObsCompleted
A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy
- Outcome
- Finished, no results posted
- Phase
- Obs
- Status
- Completed
- Study type
- Observational
- Start
- 3 April 2019
- Expected end
- 30 September 2023
- Enrollment
- 238 participants
- Sites
- 1
- Primary outcomes
- median survival; progressive-free survival
- Sponsor
- Other gov
- Results posted
- No
- Last update
- 13 November 2023
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 5
- BackgroundHuman Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Bio… DOI 10.1097/mpa.0000000000000597↗
- BackgroundCarboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal A… DOI 10.1093/jnci/djv132↗
- BackgroundPancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. DOI 10.1093/jnci/djt347↗
- BackgroundHuman equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. DOI 10.1053/j.gastro.2008.09.067↗
- BackgroundImmunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mech… DOI 10.1158/1078-0432.ccr-05-2655↗